Nahas Eliana Aguiar Petri, de Almeida Bruno da Rosa, Buttros Daniel de Araújo Brito, Véspoli Heloísa De Luca, Uemura Gilberto, Nahas-Neto Jorge
Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Júlio de Mesquita Filho - UNESP, Botucatu, SP, Brasil.
Rev Bras Ginecol Obstet. 2012 Dec;34(12):555-62. doi: 10.1590/s0100-72032012001200005.
To assess the occurrence of metabolic syndrome (MetS) in postmenopausal breast cancer survivors.
A total of 158 breast cancer survivors were included in this cross-sectional study. Eligibility criteria were: women with amenorrhea >12 months and age ≥45 years, treated for breast cancer and no metastasis for at least five years. Clinical history and anthropometric indicator data (body mass index (BMI), and waist circumference, (WC) were collected. Biochemical parameters, including total cholesterol, HDL, LDL, triglycerides (TG), glucose and C-reactive protein (CRP), were measured. MetS was diagnosed as the presence of at least three of the following diagnostic criteria: WC>88 cm, blood pressure≥130/85 mmHg, triglycerides≥150 mg/dl, HDL <50 mg/dL,and glucose≥100 mg/dL. The Student's t-test and χ2 test were used for statistical analysis.
The mean age of breast cancer survivors was 63.1±8.6 years, with a mean follow-up of 9.1±4.0 years. MetS was diagnosed in 48.1% (76/158) and the most prevalent diagnostic criterion was abdominal obesity (WC>88 cm), affecting 54.4% (86/158) of the women. The patients without MetS had a longer follow-up compared those with MetS (p<0.05). Regarding the current BMI, PN average, those without MetS were overweight, and those with MetS were obese (p<0.05). Among the latter, comparison of BMI at the time of cancer diagnosis and current BMI (27.8±5.4 versus 33.4±5.4 kg/m²) showed a significant weight gain (p<0.05). Mean CRP values were higher in women with MetS (p<0.05). In the comparison of tumor characteristics and cancer treatments there was no difference between groups (p>0.05).
Postmenopausal breast cancer survivors had a higher risk of developing metabolic syndrome and central obesity.
评估绝经后乳腺癌幸存者代谢综合征（MetS）的发生率。
本横断面研究共纳入158例乳腺癌幸存者。纳入标准为：闭经超过12个月且年龄≥45岁，接受过乳腺癌治疗且至少五年无转移。收集临床病史和人体测量指标数据（体重指数（BMI）和腰围（WC））。测量生化参数，包括总胆固醇、高密度脂蛋白、低密度脂蛋白、甘油三酯（TG）、血糖和C反应蛋白（CRP）。MetS被诊断为符合以下至少三项诊断标准：WC>88 cm、血压≥130/85 mmHg、甘油三酯≥150 mg/dl、高密度脂蛋白<50 mg/dL以及血糖≥100 mg/dL。采用Student's t检验和χ2检验进行统计分析。
乳腺癌幸存者的平均年龄为63.1±8.6岁，平均随访时间为9.1±4.0年。48.1%（76/158）的患者被诊断为MetS，最常见的诊断标准是腹型肥胖（WC>88 cm），影响了54.4%（86/158）的女性。未患MetS的患者随访时间比患MetS的患者更长（p<0.05）。就当前BMI而言，总体平均水平上，未患MetS的患者超重，患MetS的患者肥胖（p<0.05）。在后者中，癌症诊断时的BMI与当前BMI比较（27.8±5.4对33.4±5.4 kg/m²）显示体重显著增加（p<0.05）。MetS女性的平均CRP值更高（p<0.05）。在肿瘤特征和癌症治疗的比较中，两组之间无差异（p>0.05）。
绝经后乳腺癌幸存者发生代谢综合征和中心性肥胖的风险更高。
